上海莱士: 关于回购公司股份的进展公告

Core Viewpoint - Shanghai Laishi Blood Products Co., Ltd. has approved a share repurchase plan to enhance employee stock ownership and equity incentives, with a total repurchase amount ranging from RMB 250 million to RMB 500 million, at a maximum price of RMB 9.55 per share [1] Group 1: Share Repurchase Plan - The company plans to repurchase shares using self-owned or raised funds through centralized bidding in the secondary market [1] - The repurchase period is set for 12 months from the date of shareholder approval, with the possibility of early termination if certain conditions are met [1] Group 2: Progress of Share Repurchase - As of July 31, 2025, the company has repurchased a total of 65,321,952 shares, accounting for 0.98% of the total share capital, with a total transaction amount of approximately RMB 448.67 million [2] - The highest transaction price during the repurchase was RMB 7.09 per share, while the lowest was RMB 6.62 per share [2] Group 3: Compliance and Future Plans - The company's share repurchase activities comply with relevant regulations and guidelines set by the Shenzhen Stock Exchange and the China Securities Regulatory Commission [2][3] - The company will continue to implement the repurchase plan based on market conditions and will fulfill information disclosure obligations as required by law [3]